Articles tagged with Drug Resistance
Researchers at Tokyo Medical and Dental University have developed a liquid biopsy that can determine if an esophageal cancer patient will respond to certain treatments. The biopsy uses a panel of mRNAs and microRNAs to predict patient outcomes, with improved accuracy when combined with tumor size data.
A new study published in Science Translational Medicine reveals that consecutive molecular modifications of the androgen receptor can contribute to drug resistance in prostate cancer. Researchers identified a potential treatment approach using an ACK1 inhibitor to block this resistance.
Researchers have reported encouraging early-stage data for the Phase 1 clinical trial of INB-200, a gamma-delta T cell-based immunotherapy. All patients enrolled in the trial have exceeded their expected progression-free survival, with two patients exceeding overall survival as well. The treatment shows promising activity against gliob...
Deep nerve stimulation using custom-wired electrodes and wireless implantable systems significantly lowers systolic blood pressure by up to 16% in two hours. The technology targets hypertension, a leading cause of death globally, affecting over 1 billion people.
A recent study published in Frontiers in Cardiovascular Medicine found that transcranial direct current stimulation (tDCS) can lower blood pressure in patients with resistant hypertension. After a single session or ten sessions, the treatment reduced peripheral and central blood pressure in some patients by up to 15 mmHg.
Researchers have identified glycans in mucus that can prevent Candida albicans from causing infection. These molecules can be used to develop new antifungal medicines or make disease-causing fungus more susceptible to existing drugs.
A Phase 3 clinical trial is investigating the effectiveness of a combination of two immunotherapy drugs, nemvaluekin alfa and pembrolizumab, compared to standard chemotherapy for patients with platinum-resistant ovarian cancer. The trial aims to provide a novel treatment option with better efficacy and safety profiles.
Researchers have identified new biomarkers to detect non-small cell lung cancer in its early stages through a blood test, offering improved survival chances. The approach can also identify potential drug resistance, allowing clinicians to choose alternative treatment options.
Researchers at Rice University have developed molecular machines that can kill bacteria using visible light, targeting gram-negative and gram-positive bacteria. The breakthrough study uses rotors spinning at millions of times per second to break up biofilms and persister cells, making these infections more treatable.
Researchers from UToledo found that a dominant gut bacteria species, Coprococcus comes, can break down quinapril and ramipril, reducing their efficacy. This study provides insights into the impact of gut bacteria on blood pressure medication, potentially leading to new ways to overcome treatment-resistant hypertension.
Researchers at Gladstone Institutes have developed a novel class of therapeutics called feedback disruptors that target viral proteins' negative feedback loops. These drugs break the genetic feedback circuits, causing infected cells to self-destruct and stopping infection in its tracks.
Researchers developed an algorithm to quickly identify two cancer drugs that work well together, reducing testing time from three years to eight weeks. The new method uses gene expression data to prioritize potential combinations and has been confirmed in lab tests.
Researchers at H. Lee Moffitt Cancer Center & Research Institute have identified key factors impacting the effectiveness of adaptive therapy in cancer treatment. The study found that spatial organization and competition between drug-resistant cells play a crucial role in determining the success of adaptive therapy.
Researchers have discovered a way to suppress a specific protein that promotes resistance to drugs commonly used to treat AML patients. This breakthrough has the potential to revolutionize treatment and prolong survival for those affected by the disease.
Researchers developed a deep learning-based model to predict drug-drug interactions using gene expression data. The DeSIDE-DDI model can identify potentially dangerous pairs and act as a drug safety monitoring system, helping establish the correct usage of drugs in the development phase.
Researchers at Brookhaven National Laboratory discovered an aberrant protein that mimics the action of aminoglycoside antibiotics, which could help scientists understand how those drugs kill bacterial cells. The newly identified protein could lead to the development of new inhibitors to target bacterial growth.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.
Researchers found six cases of drug-resistant Aspergillus fumigatus infection linked to environmental spores. The fungus, common in soil and compost, has become resistant to antifungal drugs due to agricultural use, posing a growing threat to lung health.
A recent study found that extra copies of the 3p25.3 region of DNA can lead to chemotherapy resistance in germ cell cancer. The research suggests this abnormality may be a key factor in predicting patient outcomes and could help identify those at high risk, allowing for alternative treatment options
Researchers at Queen Mary University of London identified a way to overcome resistance to cancer drugs in leukemia cells by manipulating cellular pathways. By using a sequential treatment approach, the team was able to kill about 50% of leukemia samples and potentially develop a new treatment strategy for this devastating disease.
Researchers at Shibaura Institute of Technology discovered that tocotrienols, a subtype of vitamin E, can lower body weight, reduce white adipose tissue, and protect the liver in mice fed with a high-fat diet. The study suggests a potential compound to prevent obesity and its secondary diseases.
A decision-support framework was developed by management science researchers to help clinicians make informed decisions about opioid prescribing. The framework incorporates multiple factors, including recovery time, pain intensity, and patient history, to provide a quantitative model of the prescribing process.
Scientists have identified a potential new antibiotic candidate from the rare soil microbe Lentzea flaviverrucosa. The discovery was made using genomics-based approaches and shows that this actinomycete produces two different bioactive molecules that are active against various types of cancer cells.
Gram-negative bacteria use a crucial component in their outer membrane that shields them from immune system and antibiotics. Researchers discovered the structure of an enzyme linked to this process, which could lead to custom-designed drugs to counteract these deadly bacteria.
PrEP users in Germany experienced infrequent testing, with 26.3% not following recommended frequencies for HIV, STI, and renal function testing. Regular testing is crucial to prevent missed diagnoses and manage asymptomatic STIs, particularly in MSM populations.
Researchers found that a certain gut bacterium can break down quinapril, an ACE inhibitor used to treat high blood pressure, reducing its effectiveness. The study suggests that the same drug may not be suitable for everyone due to unique gut microbial compositions.
Researchers at Tel Aviv University developed a drug delivery system based on lipid nanoparticles that utilize RNA to boost personalized cancer care. The nanodrug enhances chemotherapy effectiveness and reinvigorates the immune system, increasing sensitivity to cancer cells.
A new wireless implant has the potential to treat neuropathic pain resistant to medical therapy, offering a minimally invasive alternative to surgery. The device uses bioelectronic therapy to stimulate peripheral nerves from within blood vessels, providing precise placement and predictable outcomes.
A Johns Hopkins-led study published in New England Journal of Medicine found that convalescent plasma from recovered COVID-19 patients can effectively treat outpatients, with a 54% reduced need for hospitalization. The therapy's effectiveness increases with earlier administration within five days after diagnosis.
Researchers at TTUHSC will investigate common mechanisms of resistance and sensitivity in alternate telomere lengthening (ALT) cancers, with a focus on targeting ATM kinase inhibitors for therapy. The team aims to develop clinical trials for patients with ALT+ cancers.
Researchers at Yale have identified a remdesivir-resistant variant of the SARS-CoV-2 virus in an immunocompromised patient. The discovery raises concerns about drug resistance in COVID-19 patients, particularly those with weakened immune systems.
A team of researchers led by Tejas Patil is investigating how the EGFR and MET signaling pathways contribute to treatment resistance in RET-positive lung cancer. The study aims to determine whether combining a RET-targeted therapy with amivantamab, a bi-specific antibody blocking both pathways, can improve patient outcomes.
Researchers found that the Pfizer antiviral drug Paxlovid still quashes COVID by targeting a key protein involved in replicating the virus. The study also identified signs of emerging mutations, indicating an urgent need for new drugs to combat potential resistance.
A study published in Frontiers in Microbiology has found that machine learning analysis of microscopy images can be used to identify bacteria resistant to antibiotics. Researchers discovered that shape changes in bacterial cells can predict drug resistance, suggesting a new approach for detecting and predicting drug resistance.
A new UMaine study shows that a specific combination of pathogens and drugs can effectively treat fungal lung infections. Researchers found that Pseudomonas aeruginosa works with fluconazole to eliminate drug tolerance and clear Candida albicans infection, suggesting that nutrient availability can impact treatment efficacy.
Researchers found that hydroxychloroquine inhibits pathways that drive resistance to cisplatin in head and neck cancers, restoring tumor-killing effects. The study paves the way for a clinical trial combining hydroxychloroquine and cisplatin to treat chemotherapy-resistant patients.
A team from UNIGE has identified a potential target for restoring the efficacy of standard breast cancer treatment. The loss of SPRED2 protein leads to tumor proliferation even with tamoxifen treatment. Combining tamoxifen with an inhibitor of estrogen-independent cell activation may be promising for resistant patients.
Researchers at the University of Pennsylvania have identified a key factor in T-cell leukemia disease relapse - genome refolding. The study found that cancer cells adapt to targeted therapy by changing the folding of their genome, driven by transcription factor repositioning.
Researchers from Tel Aviv University found that hyperbaric oxygen therapy (HBOT) relieves PTSD symptoms in treatment-resistant veterans, improving brain function and microstructure. The breakthrough study provides new hope for PTSD sufferers, offering an objective diagnostic tool and potential long-term improvements.
Researchers have discovered a protein that plays a key role in the malaria parasite, leading to a potential new way to fight the disease. Deactivating this protein reduces the growth of the parasite by over 75%, making it a promising target for treatment development.
Researchers discover that chemotherapy triggers the secretion of mucins in colorectal cancer cells, forming a physical barrier that prevents drugs from reaching their intended target. The study found potential new biomarkers for disease prognosis and a promising treatment strategy using NCX blockers like SN-6.
Researchers found that compost and compost-enriched soils contain high concentrations of Aspergillus fumigatus spores, which can cause serious lung infections. Handling compost exposes individuals to large numbers of aerosolized spores, highlighting the need for behavioral changes and industry action
Two independent teams of researchers have found the molecular mechanism of action of praziquantel, the only approved drug to treat schistosomiasis. The drug binds to a specific type of channel in the cell membrane, causing calcium ions influx and resulting in worm paralysis and death.
Researchers at Michigan Medicine have developed a new genetic tool to study Candida auris, revealing key factors behind its shape-shifting abilities and drug resistance. The study could aid in understanding the fungus's transmission on hospital surfaces.
Researchers developed a model of drug resistance in melanoma, revealing mechanisms involving extrachromosomal DNA amplifications and intrachromosomal chromosomal rearrangements. The study found that different forms of DNA offer 'fitness' advantages to tumor cells under varying therapeutic conditions.
Researchers identified 'pre-resistance' signs in bacteria, predicting future resistance to antibiotics. This discovery allows doctors to select the best treatments for bacterial infections and paves the way for personalized genomic therapy.
Researchers have discovered that a common class of targeted therapies can help more colorectal cancer patients than previously thought. By analyzing cell studies and computer modeling, the team identified 10 distinct RAS mutations that do not preclude the use of EGFR inhibitors, which are already approved for other uses.
A new report proposes a clearer definition of treatment-resistant depression, aiming to improve treatment outcomes. The study found that only about a third of studies in TRD enroll participants who met the most common definition, highlighting the need for a standardized approach.
Scientists at Gladstone Institutes developed a new class of antiviral therapy that can track the evolution of SARS-CoV-2, reducing the chance of reduced efficacy against new variants. The single-dose intranasal treatment showed significant reduction in viral load and prevented disease in animals.
Researchers discovered that blood stem cells use high-energy fatty acids from the body's fat stores to power up their response to infection. This finding could lead to new approaches in treating bacterial infections, particularly in vulnerable and older individuals.
A new protein variant called CLIP-170S allows cancer cells to dodge chemotherapy drugs, rendering them ineffective. Researchers discovered this variant in more than 60% of patients with gastric cancer and are exploring a combination therapy involving imatinib to overcome resistance.
Researchers identified a mechanism for how genetically defective cells mutate to survive stressful situations, such as drug treatment. Understanding this resistance mechanism could lead to the development of new strategies to delay or prevent cancer drug resistance.
Researchers have developed a prostate cancer organoid that can mimic the patient-specific microenvironment, opening up new avenues for targeted treatments. The study reveals that extracellular matrix regulates EZH2 activity and efficacy of inhibitors, as well as identifies potential new therapeutic targets like DRD2.
A researcher at MUSC's Hollings Cancer Center is developing 'living drugs' by precision-engineering CAR Tregs to treat autoimmune diseases. The CAR Tregs can delay or reduce damaging inflammation, offering a potential solution for conditions like Type 1 diabetes.
Researchers at Baylor College of Medicine identified over 300 genes with altered expression in advanced cancers due to genomic structural variations. The study found associations between tumor genomic rearrangements and altered metabolism-associated gene expression, suggesting potential mechanisms for therapy resistance. These findings...
Newborns with drug-resistant seizures often develop lifelong epilepsy and cognitive disabilities. Researchers at Kennedy Krieger Institute have identified a molecular mechanism that offers promise for understanding and developing novel treatment options.
Researchers developed a blood test that can detect prostate cancer patients who are resistant to chemotherapy drug docetaxel, enabling early detection and personalized treatment. The test analyzes circulating tumor cells in the bloodstream, revealing patterns that predict disease progression and survival.
Researchers found that restoring NXTAR expression can suppress prostate tumor growth, suggesting a new approach to treating hormone-resistant prostate cancer. The study identified an RNA molecule called NXTAR that plays a key role in regulating the androgen receptor, a protein driving prostate tumor growth.
Researchers at Skoltech propose a method for interpreting brain activity data that is up to five times more accurate than the conventional technique. This method can help treat drug-resistant epilepsy and understand cognitive processes in the healthy brain.
A genetic signature has been discovered that can identify drivers of poor outcomes in advanced estrogen-receptor positive (ER+) breast cancer. The signature detects the presence of mutations and translocations in the ER gene that confer tumor independence from estrogen, making it resistant to current therapies.